Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~SLE patients~* Female patients aged ≤ 35 years~* Fulfilling the American College of Rheumatology (ACR) criteria for the classification of SLE~* Having received a stable dose of prednisolone and/or other immunosuppressive agents within 3 months of study entry~* Able to give written informed consent~Controls~* Women aged ≤ 35 years, matched those of SLE patients recruited~* No known chronic medical diseases~* Not receiving any long-term medications including herbs~Exclusion Criteria:~* History of allergy to HPV vaccines

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Vaccine arm (Type: ACTIVE_COMPARATOR): subjects receiving vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).